Tuesday 27 September 2022 - 04:39
In Business 42 Years - Since 1980
Recently, we have been and are currently operating with: (1) staff shortages related to CV19 and other factors, (2) vacations, (3) a significant health burden for one senior staff member, and (4) dedication of substantial internal resources to a major public-service project. This situation is expected to continue through Sunday, September 11. During this time, we have been and expect to continue entering, processing and shipping orders normally for in-stock products. However, non-order-related communications and production of backordered products will be subject to some unusual delays. We apologize very much for this situation and appreciate your understanding.
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
N-5688 Niraparib, p-Toluenesulfonate Salt, >99%
Synonyms : [MK-4827]
Related Terms : [Zejula]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 42
- 43
- 38
- 6,100
- In stock
- 10 mg
- 56
- 58
- 51
- 8,100
- In stock
- 25 mg
- 75
- 77
- 69
- 10,800
- In stock
- 50 mg
- 96
- 99
- 88
- 13,900
- In stock
- 100 mg
- 143
- 148
- 132
- 20,600
- In stock
- 200 mg
- 242
- 250
- 224
- 34,900
- In stock
- 500 mg
- 477
- 494
- 441
- 68,800
- In stock
- 1 g
- 695
- 720
- 643
- 100,300
- In stock
- 2 g
- 1,130
- 1,171
- 1,046
- 163,000
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 492.59
- C19H20N4O•C7H8O3S
- [1038915-73-9]
Solubility: DMSO.
- Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells. In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities. Mueller S., et al. "Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma." Anticancer Res. 33: 755-762 (2013).
- A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day. Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. Sandhu S.K., et al. "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncol. 14: 882-892 (2013).
- Related CAS numbers: 1038915-64-8 for the hydrochloride salt; 1038915-60-4 for the free base; 1171196-88-5 for the sulfate salt.
- Niraparib Tosylate monohydrate is the active ingredient in the drug sold under the trade name Zejula®. This drug has been approved in at least one country for use in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. NOTE: THE NIRAPARIB TOSYLATE MONOHYDRATE SOLD BY THE LC LABORATORIES IS NOT ZEJULA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
